Education
About Us
Working with TipRanks
Follow Us
Taysha Gene Therapies (TSHA)
NASDAQ:TSHA
TSHA Analyst Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
TSHA Stock 12 Month Forecast
Average Price Target
$6.63
▲(486.73% Upside)
| Highest Price Target$8.00 | Average Price Target$6.63 | Lowest Price Target$5.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Wells Fargo
Reiterated
04/03/25
Truist Financial
Reiterated
02/27/25
Canaccord Genuity
Reiterated
02/27/25
JMP Securities
Reiterated
02/27/25
Needham
Reiterated
02/26/25
Chardan Capital
$7
Buy
519.47%
Upside
Reiterated
11/14/24
3 Best Stocks to Buy Now, 11/14/2024, According to Top Analysts - TipRanks.comTaysha Gene Therapies (TSHA) This biotechnology company develops innovative cell therapies for the treatment of cancer and other serious diseases. Today, Chardan Capital analyst Geulah Livshits reiterated a Buy rating on the stock with a price target of $7. In the last three months, all six Top Analysts covering the stock have rated it a Buy. Altogether, their 12-month price targets imply an upside of over 221%.
Piper Sandler
$7
Buy
519.47%
Upside
Assigned
11/14/24
Piper Sandler Releases a Buy Rating on Taysha Gene Therapies (TSHA)
Cantor Fitzgerald
$7
Buy
519.47%
Upside
Assigned
11/13/24
Cantor Fitzgerald Reaffirms Their Buy Rating on Taysha Gene Therapies (TSHA)
BMO Capital
$5
Buy
342.48%
Upside
Assigned
11/13/24
Buy Rating Justified for Taysha Gene Therapies Amid Promising TSHA-102 Developments and Upcoming Catalysts
Robert W. Baird
$7
Buy
519.47%
Upside
Reiterated
11/12/24
Positive Buy Rating for Taysha Gene Therapies Amidst Competitive Advantages Over Neurogene
Jefferies
$8
Buy
607.96%
Upside
Reiterated
08/12/24
Buy Rating Affirmed for Taysha Gene Therapies Amid Strategic Planning and Potential Drug Efficacy
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Wells Fargo
Reiterated
04/03/25
Truist Financial
Reiterated
02/27/25
Canaccord Genuity
Reiterated
02/27/25
JMP Securities
Reiterated
02/27/25
Needham
Reiterated
02/26/25
Chardan Capital
$7
Buy
519.47%
Upside
Reiterated
11/14/24
3 Best Stocks to Buy Now, 11/14/2024, According to Top Analysts - TipRanks.comTaysha Gene Therapies (TSHA) This biotechnology company develops innovative cell therapies for the treatment of cancer and other serious diseases. Today, Chardan Capital analyst Geulah Livshits reiterated a Buy rating on the stock with a price target of $7. In the last three months, all six Top Analysts covering the stock have rated it a Buy. Altogether, their 12-month price targets imply an upside of over 221%.
Piper Sandler
$7
Buy
519.47%
Upside
Assigned
11/14/24
Piper Sandler Releases a Buy Rating on Taysha Gene Therapies (TSHA)
Cantor Fitzgerald
$7
Buy
519.47%
Upside
Assigned
11/13/24
Cantor Fitzgerald Reaffirms Their Buy Rating on Taysha Gene Therapies (TSHA)
BMO Capital
$5
Buy
342.48%
Upside
Assigned
11/13/24
Buy Rating Justified for Taysha Gene Therapies Amid Promising TSHA-102 Developments and Upcoming Catalysts
Robert W. Baird
$7
Buy
519.47%
Upside
Reiterated
11/12/24
Positive Buy Rating for Taysha Gene Therapies Amidst Competitive Advantages Over Neurogene
Jefferies
$8
Buy
607.96%
Upside
Reiterated
08/12/24
Buy Rating Affirmed for Taysha Gene Therapies Amid Strategic Planning and Potential Drug Efficacy
Best Analysts Covering Taysha Gene Therapies
Which Analyst Should I Follow If I Want to Buy TSHA and Sell After:
1 Month
xxx
Success Rate
10/21 ratings generated profit
Average Return
+3.08%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 47.62% of your transactions generating a profit, with an average return of +3.08% per trade.
3 Months
xxx
Success Rate
6/21 ratings generated profit
Average Return
-4.22%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 28.57% of your transactions generating a profit, with an average return of -4.22% per trade.
1 Year
2 Years
xxx
Success Rate
4/20 ratings generated profit
Average Return
-26.91%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 20.00% of your transactions generating a profit, with an average return of -26.91% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
TSHA Analyst Recommendation Trends
Rating
Oct 24
Nov 24
Jan 25
Feb 25
Apr 25
Strong Buy
11
15
16
17
6
Buy
2
2
1
2
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
17
17
19
7
Each month's total comprises the sum of three months' worth of ratings.
TSHA Financial Forecast
TSHA Stock Forecast FAQ
What is TSHA’s average 12-month price target, according to analysts?
Based on analyst ratings, Taysha Gene Therapies’s 12-month average price target is $6.63.
What is TSHA’s upside potential, based on the analysts’ average price target?
Taysha Gene Therapies has 486.73% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TSHA a Buy, Sell or Hold?
Taysha Gene Therapies has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
What is Taysha Gene Therapies’s price target?
The average price target for Taysha Gene Therapies is $6.63. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $8.00 ,the lowest forecast is $5.00. The average price target represents 486.73% Increase from the current price of $1.13.
The highest analyst price target is $8.00 ,the lowest forecast is $5.00. The average price target represents 486.73% Increase from the current price of $1.13.
What do analysts say about Taysha Gene Therapies?
Taysha Gene Therapies’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of TSHA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.